Sort
40,608 grants matching “prostate cancer”
TARGETING THE IMMUNOSUPPRESSIVE MICROENVIRONMENT OF PROSTATE CANCER TO ENHANCE THERAPEUTIC EFFICACY OF THE IMMUNE CHECKPOINT INHIBITORS
$1,420,835Icahn School Of Medicine At Mount Sinai · · FY2025 · Defense Health Agency
IN VIVO IMAGING OF BRANCHED CHAIN AMINO ACID METABOLISM IN PROSTATE CANCER
$1,420,215The Leland Stanford Junior University · · FY2011 · Department of Defense
Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies
$1,420,204Anish Thomas · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Paracrine TGF-Beta Signaling in Tumor Initiation and Progression
$1,419,991Lynn M Matrisian · Vanderbilt University · U54 · FY2010 · CA
Uncovering diverse genotype-phenotype relationships in prostate cancer
$1,419,627John Kyung Lee · Fred Hutchinson Cancer Research Center · DP2 · FY2021 · CA
SBIR Phase II: A Cell Analysis Platform for Low-cost, Rapid Diagnosis of Sepsis Using Microfluidic Technologies
$1,419,607Mara Macdonald · Cytovale, Inc · · FY2014 · TIP
Gene Discovery
$1,418,774Ira Pastan · Basic Sciences · Z01 · FY2007 · CA
Assessment of serum peptide profiling to detect cancer-specific patterns
$1,418,018Paul Tempst · Sloan-Kettering Inst Can Research · U24 · FY2010 · CA
Cancer Epidemiology Cohort in Male Health Professionals
$1,417,851Walter C. Willett · Harvard School Of Public Health · U01 · FY2023 · CA
Assessment of serum peptide profiling to detect cancer-specific patterns
$1,417,183Paul Tempst · Sloan-Kettering Inst Can Research · U24 · FY2009 · CA
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center
$1,416,545Charles L Sawyers · Sloan-Kettering Inst Can Research · U54 · FY2020 · CA
Discovery Expansion and Replication
$1,415,741Douglas Frederick Easton · Harvard School Of Public Health · U19 · FY2012 · CA
DIFFERENTIAL SPLICING OF ONCOGENES AND TUMOR SUPPRESSOR GENES IN AFRICAN AND CAUCASIAN-AMERICAN POPULATION: CONTRIBUTING FACTOR IN PROSTATE CANCER DI
$1,413,554George Washington University (The) · · FY2013 · Department of the Army
The LUCINDA Trial
$1,413,113Tracy A. Butler · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · AG
SUPPRESSION OF BRCA2 BY MUTANT MITOCHONDRIAL DNA IN PROSTATE CANCER
$1,412,815The University Of Texas Southwestern Medical Center · · FY2010 · Department of Defense
Center of Excellence in Eliminating Disparities
$1,412,350Elizabeth Ann Calhoun · University Of Illinois At Chicago · P60 · FY2012 · MD
ELASTOGRAPHY: CLINICAL AND BASIC SCIENCE
$1,411,402University Of Texas Hlth Sci Ctr Houston · P01 · FY2003 · EB
Cellular Interactions with Thrombospondin
$1,411,277David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2023 · CA
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients
$1,411,059Brent K. Hollenbeck · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
NATIONAL BLACK LEADERSHIP INITIATIVE ON CANCER II: NETWO
$1,409,849Morehouse School Of Medicine · U01 · FY2001 · CA
The Biology of Prostate Cancer Skeletal Metastases
$1,409,508Evan Todd Keller · University Of Michigan At Ann Arbor · P01 · FY2013 · CA
Molecular Imaging of Cancer and Its Response to Therapy
$1,409,387Kenneth A. Krohn · University Of Washington · P01 · FY2011 · CA
SOCIAL ISOLATION, LONELINESS, AND HEALTH OUTCOMES AMONG PROSTATE CANCER SURVIVORS
$1,408,488The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2025 · Defense Health Agency
CARCINOMA-ASSOCIATED FIBROBLASTS FROM AFRICAN AMERICAN PROSTATE CANCER PROMOTE AGGRESSIVE TUMORS: IMPLICATIONS FOR DEVELOPING NOVEL THERAPY
$1,407,580University Of California Irvine · · FY2019 · Defense Health Agency
High throughput infrastructure for reaction screening and bioassays
$1,407,199Robert Graham Cooks · Purdue University · UH3 · FY2024 · TR